Łapińska Grażyna, Bryszewska Małgorzata, Fijołek-Warszewska Agnieszka, Kozłowicz-Gudzińska Izabella, Ochman Paweł, Sackiewicz-Słaby Agata
Department of Nuclear Medicine and Oncological Endocrinology, Maria Skłodowska-Curie Cancer Centre-Institute, ul. W.K. Roentegena 5, Warsaw, Poland.
Nucl Med Rev Cent East Eur. 2011;14(1):16-20. doi: 10.5603/nmr.2011.0004.
Positron emission tomography (PET) combined with computer tomography (CT) using (68)Ga-DOTATATE is a promising method for the evaluation of patients with recognised or suspected neuroendocrine tumours (NET). The aim of this study was to assess the diagnostic value of (68)Ga-DOTATATE PET/CT in the visualisation of the expression of somatostatin receptors (SSTR) and identification of new lesions.
Between December 2009 and January 2011 ninety-seven patients with confirmed (88 cases) or suspected (9 cases) NET underwent (68)Ga DOTATATE PET/CT. The primary, confirmed or suspected, NET localizations were: GEP tumours--71 patients; medullary thyroid carcinoma--4 patients; cancer of an unknown primary--14 patients; and NET in other localisations--8 patients. PET/CT acquisitions were performed using standard techniques, 45 to 60 minutes after the intravenous injection of 111-185 MBq (68)Ga-DOTATATE.
(68)Ga-DOTATATE PET/CT detected the presence of lesions demonstrating the somatostatin receptor affinity in 50 of the 97 patients (51.5%) and was negative in 47 patients (48.5%). Among 14 patients with metastatic unknown primary cancer, in 5 patients (45.5%) the primary tumour site was identified, and in 4 patients with medullary thyroid cancer distant metastases with SSTR expression were localized in only one patient.
Our findings confirm the diagnostic role of (68)Ga-DOTATATE PET/CT as an accurate method of identifying primary tumours and distant metastases. It provides information on tumour cell receptors status, which has a significant bearing on planning target radionuclide therapy. Overall, (68)Ga-DOTATATE PET/CT can be used in staging, re-staging, and in regular follow up of oncology patients.
正电子发射断层扫描（PET）联合计算机断层扫描（CT）使用（68）Ga - DOTATATE是评估已确诊或疑似神经内分泌肿瘤（NET）患者的一种有前景的方法。本研究的目的是评估（68）Ga - DOTATATE PET/CT在生长抑素受体（SSTR）表达可视化及新病灶识别方面的诊断价值。
2009年12月至2011年1月期间，97例确诊（88例）或疑似（9例）NET患者接受了（68）Ga - DOTATATE PET/CT检查。确诊或疑似的原发性NET定位如下：胃肠道胰腺（GEP）肿瘤——71例患者；甲状腺髓样癌——4例患者；原发灶不明的癌症——14例患者；其他部位的NET——8例患者。在静脉注射111 - 185 MBq（68）Ga - DOTATATE后45至60分钟，使用标准技术进行PET/CT采集。
（68）Ga - DOTATATE PET/CT在97例患者中的50例（51.5%）检测到显示生长抑素受体亲和力的病灶，47例患者（48.5%）结果为阴性。在14例转移性原发灶不明的癌症患者中，5例（45.5%）确定了原发肿瘤部位，4例甲状腺髓样癌患者中，只有1例患者检测到有SSTR表达的远处转移灶。
我们的研究结果证实了（68）Ga - DOTATATE PET/CT作为识别原发性肿瘤和远处转移灶的准确方法的诊断作用。它提供了有关肿瘤细胞受体状态的信息，这对规划靶向放射性核素治疗具有重要意义。总体而言，（68）Ga - DOTATATE PET/CT可用于肿瘤患者的分期、重新分期及定期随访。
